BR0015346A - Formulação farmacêutica contendo tolterodina e seu uso - Google Patents

Formulação farmacêutica contendo tolterodina e seu uso

Info

Publication number
BR0015346A
BR0015346A BR0015346-0A BR0015346A BR0015346A BR 0015346 A BR0015346 A BR 0015346A BR 0015346 A BR0015346 A BR 0015346A BR 0015346 A BR0015346 A BR 0015346A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
formulation containing
tolterodine
containing tolterodine
hours
Prior art date
Application number
BR0015346-0A
Other languages
English (en)
Inventor
Lisbeth Nilvebrant
Bengt Hallen
Birgitta Olsson
Jan Stroembom
Torkel Gren
Anders Ringberg
Martin Wikberg
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56290073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0015346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/002052 external-priority patent/WO2000027364A1/en
Priority claimed from SE0000782A external-priority patent/SE0000782D0/xx
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of BR0015346A publication Critical patent/BR0015346A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO FARMACêUTICA CONTENDO TOLTERODINA E SEU USO". A presente invenção se refere a uma formulação farmacêutica contendo tolterodina ou um composto correlacionado à tolterodina ou um sal farmacologicamente aceitável do mesmo como ingrediente ativo, em que a formulação exibe uma liberação controlada in vitro do ingrediente ativo em um tampão de fosfato com pH 6,8 de não menos que cerca de 80% após 18 horas e após administração oral a um paciente, é capaz de manter um nível de soro substancialmente constante da porção ou porções ativas por 24 horas. A invenção também se refere ao uso da formulação farmacêutica para tratamento de distúrbios de bexiga urinária com excesso de atividade e distúrbios gastrointestinais.
BR0015346-0A 1999-11-11 2000-10-24 Formulação farmacêutica contendo tolterodina e seu uso BR0015346A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
SE0000782A SE0000782D0 (sv) 1999-11-11 2000-03-09 Pharmaceutical formulation and its use
PCT/SE2000/002061 WO2001034139A1 (en) 1999-11-11 2000-10-24 Pharmaceutical formulation containing tolterodine and its use

Publications (1)

Publication Number Publication Date
BR0015346A true BR0015346A (pt) 2002-06-25

Family

ID=56290073

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015346-0A BR0015346A (pt) 1999-11-11 2000-10-24 Formulação farmacêutica contendo tolterodina e seu uso

Country Status (24)

Country Link
US (1) US6630162B1 (pt)
EP (1) EP1227806B1 (pt)
JP (1) JP2003513918A (pt)
KR (2) KR20070091374A (pt)
CN (1) CN100353935C (pt)
AT (1) ATE300941T1 (pt)
AU (1) AU784104B2 (pt)
BR (1) BR0015346A (pt)
CA (1) CA2387973C (pt)
CZ (1) CZ304671B6 (pt)
DE (1) DE60021749T2 (pt)
DK (1) DK1227806T3 (pt)
EE (1) EE05191B1 (pt)
ES (1) ES2245320T3 (pt)
HK (1) HK1054196B (pt)
HU (1) HUP0203028A3 (pt)
MX (1) MXPA02004574A (pt)
NO (1) NO20022264L (pt)
NZ (1) NZ518309A (pt)
PL (1) PL356166A1 (pt)
PT (1) PT1227806E (pt)
SI (1) SI1227806T1 (pt)
SK (1) SK6412002A3 (pt)
WO (1) WO2001034139A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
SK6412002A3 (en) * 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
DE10224556A1 (de) * 2002-05-31 2004-01-08 Grünenthal GmbH 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE60332387D1 (de) * 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
CA2514022C (en) * 2003-01-22 2010-07-13 Pfizer Health Ab Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
SE0300830D0 (sv) * 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
CN100382794C (zh) * 2004-08-30 2008-04-23 鲁南制药集团股份有限公司 酒石酸托特罗定的分散片剂型
CN1795845B (zh) * 2004-12-23 2010-10-13 李又欣 作为毒蕈碱受体拮抗剂的3，3-二苯基丙胺衍生物注射用缓释微球制剂
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
US20070248670A1 (en) * 2006-04-21 2007-10-25 Van Den Heuvel Dennie J M Tolterodine beads
CZ298448B6 (cs) * 2006-08-09 2007-10-03 Zentiva, A. S. Farmaceutická kompozice s obsahem tolterodinu
KR100851033B1 (ko) * 2007-02-12 2008-08-12 명문제약주식회사 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
EP2173329A1 (en) * 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2009080061A1 (en) * 2007-12-20 2009-07-02 Pharmathen S.A. Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2753416A1 (en) * 2009-02-23 2010-08-26 Gopi Venkatesh Controlled release compositions comprising anti-cholinergic drugs
WO2011013082A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
US20130004545A1 (en) 2009-12-23 2013-01-03 Lupin Limited Slow release pharmaceutical compositions of iloperidone
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US8392016B2 (en) 2010-06-25 2013-03-05 LNT PM Inc. Adaptive method for manufacturing of complicated shape parts by hot isostatic pressing of powder materials with using irreversibly deformable capsules and inserts
US8940763B2 (en) 2011-05-10 2015-01-27 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
WO2016029215A1 (en) * 2014-08-22 2016-02-25 Medipath, Inc. Compositions and methods for cannabinoid coatings for use in drug delivery
AU2016388308B2 (en) 2016-01-20 2022-08-04 Theravida, Inc. Methods and compositions for treating hyperhidrosis
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
WO1993023025A1 (en) 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
JPH0710745A (ja) * 1993-06-22 1995-01-13 Tanabe Seiyaku Co Ltd 放出開始時間制御型腸デリバリー経口製剤
JP3453186B2 (ja) * 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
AU7994694A (en) 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
JP2000515525A (ja) * 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
EP0927034A1 (en) 1996-09-19 1999-07-07 American Home Products Corporation Method of treating urinary incontinence
JPH11193271A (ja) * 1997-10-31 1999-07-21 Ss Pharmaceut Co Ltd アリール酢酸アミド誘導体又はその塩及びこれを含有する医薬
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
PT1039882E (pt) * 1998-08-27 2011-01-03 Pfizer Health Ab Formulação terapêutica para administrar tolterodina com libertação controlada
SK6412002A3 (en) * 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use

Also Published As

Publication number Publication date
KR100838930B1 (ko) 2008-06-16
AU784104B2 (en) 2006-02-02
SK6412002A3 (en) 2002-09-10
NO20022264D0 (no) 2002-05-13
EP1227806A1 (en) 2002-08-07
EE05191B1 (et) 2009-08-17
HK1054196B (zh) 2008-08-01
CA2387973A1 (en) 2001-05-17
ATE300941T1 (de) 2005-08-15
SI1227806T1 (sl) 2005-12-31
MXPA02004574A (es) 2004-09-10
PL356166A1 (en) 2004-06-14
NO20022264L (no) 2002-05-13
ES2245320T3 (es) 2006-01-01
DE60021749T2 (de) 2006-04-20
HUP0203028A2 (hu) 2003-02-28
CZ20021617A3 (cs) 2002-11-13
CN100353935C (zh) 2007-12-12
CN1420767A (zh) 2003-05-28
DK1227806T3 (da) 2005-10-31
AU1319201A (en) 2001-06-06
PT1227806E (pt) 2005-10-31
KR20020062302A (ko) 2002-07-25
KR20070091374A (ko) 2007-09-10
EP1227806B1 (en) 2005-08-03
CA2387973C (en) 2009-12-22
CZ304671B6 (cs) 2014-08-27
HK1054196A1 (en) 2003-11-21
EE200200245A (et) 2003-06-16
NZ518309A (en) 2003-05-30
DE60021749D1 (de) 2005-09-08
US6630162B1 (en) 2003-10-07
JP2003513918A (ja) 2003-04-15
HUP0203028A3 (en) 2005-07-28
WO2001034139A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
BR0015346A (pt) Formulação farmacêutica contendo tolterodina e seu uso
BR0015624A (pt) Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0313424B8 (pt) forma de dosagem e processo para a preparação de uma forma de dosagem
BRPI0015284B8 (pt) formulações de hidrocodona de liberação controlada
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
PT1256340E (pt) Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
BRPI0410786A (pt) composição, uso da mesma, e, método de tratamento de um distúrbio de humor em um paciente
DK175621B1 (da) Præparater med forbedret penetration
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
ATE444061T1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin- plasmaspiegeln
ES2158101T3 (es) Formulaciones farmaceuticas efervescentes que contienen microcapsulas biodegradables de liberacion controlada.
BR0114100A (pt) Formulações de liberação controlada para administração oral
AU624793B2 (en) Antitussive liquid compositions containing phenol
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
US20090124606A1 (en) Composition for Treatment of Psychosis
HU206976B (en) Process for producing pharmaceutical compositions comprising naphthopydil, for treating diuria
BR0114339A (pt) Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina
SE0000782D0 (sv) Pharmaceutical formulation and its use
EP1148883B1 (en) Use of tricyclic antidepressants for treatment of headache

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 11 DA LPI.

B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 15 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B12B Appeal against refusal [chapter 12.2 patent gazette]